AAREY DRUGS & PHARMACEUTICALS
|
AAREY DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.49 | 2.58 | 2.79 | 2.48 | 2.80 |
| CEPS(Rs) | 2.11 | 3.37 | 3.18 | 2.86 | 3.23 |
| DPS(Rs) | - | - | - | - | 0.10 |
| Book NAV/Share(Rs) | 45.34 | 43.85 | 41.29 | 38.50 | 36.02 |
| Tax Rate(%) | 37.25 | 34.69 | 21.53 | 20.00 | 27.20 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 1.84 | 2.31 | 1.33 | 1.08 | 2.22 |
| EBIT Margin(%) | 2.12 | 2.45 | 3.08 | 3.01 | 3.16 |
| Pre Tax Margin(%) | 1.43 | 2.04 | 2.38 | 2.41 | 2.53 |
| PAT Margin (%) | 0.90 | 1.33 | 1.87 | 1.93 | 1.84 |
| Cash Profit Margin (%) | 1.28 | 1.73 | 2.13 | 2.23 | 2.13 |
| Performance Ratios | |||||
| ROA(%) | 1.41 | 2.74 | 3.05 | 3.41 | 4.15 |
| ROE(%) | 3.33 | 6.31 | 6.98 | 6.65 | 8.07 |
| ROCE(%) | 6.27 | 9.87 | 9.46 | 8.48 | 12.05 |
| Asset Turnover(x) | 1.56 | 2.06 | 1.63 | 1.77 | 2.25 |
| Sales/Fixed Asset(x) | 12.83 | 15.88 | 12.23 | 11.29 | 14.00 |
| Working Capital/Sales(x) | 4.09 | 5.35 | 3.98 | 3.70 | 4.71 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.08 | 0.06 | 0.08 | 0.09 | 0.07 |
| Receivable days | 142.04 | 110.48 | 135.22 | 122.77 | 103.43 |
| Inventory Days | 18.51 | 11.91 | 18.57 | 23.26 | 18.53 |
| Payable days | 108.80 | 86.14 | 102.62 | 72.34 | 61.48 |
| Valuation Parameters | |||||
| PER(x) | 15.93 | 16.03 | 8.33 | 5.37 | 10.33 |
| PCE(x) | 11.24 | 12.30 | 7.30 | 4.65 | 8.95 |
| Price/Book(x) | 0.52 | 0.94 | 0.56 | 0.35 | 0.80 |
| Yield(%) | - | - | - | - | 0.35 |
| EV/Net Sales(x) | 0.23 | 0.24 | 0.21 | 0.16 | 0.24 |
| EV/Core EBITDA(x) | 9.29 | 8.47 | 6.14 | 4.89 | 6.82 |
| EV/EBIT(x) | 10.94 | 9.86 | 6.67 | 5.37 | 7.43 |
| EV/CE(x) | 0.33 | 0.49 | 0.31 | 0.25 | 0.57 |
| M Cap / Sales | 0.14 | 0.21 | 0.16 | 0.10 | 0.19 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -14.98 | 41.43 | 16.10 | -15.40 | 1.74 |
| Core EBITDA Growth(%) | -25.68 | 20.55 | 17.58 | -18.84 | 12.95 |
| EBIT Growth(%) | -26.48 | 12.37 | 19.02 | -19.51 | 10.92 |
| PAT Growth(%) | -42.47 | 0.62 | 12.44 | -11.44 | 5.90 |
| EPS Growth(%) | -42.47 | -7.31 | 12.44 | -11.44 | 5.90 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.33 | 0.13 | 0.19 | 0.20 | 0.19 |
| Current Ratio(x) | 1.61 | 1.73 | 1.67 | 1.81 | 2.31 |
| Quick Ratio(x) | 1.44 | 1.62 | 1.53 | 1.64 | 1.94 |
| Interest Cover(x) | 3.10 | 5.93 | 4.40 | 5.06 | 5.03 |
| Total Debt/Mcap(x) | 0.63 | 0.13 | 0.33 | 0.58 | 0.24 |
Compare Financial Ratios of peers of AAREY DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AAREY DRUGS & PHARMACEUTICALS | ₹132.1 Cr | 12% | -5.9% | 84.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
AAREY DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AAREY DRUGS & PHARMACEUTICALS | 12% |
-5.9% |
84.1% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
